Analyst Coverage
The following organisations provide research coverage on Pharmaxis:
Bell Potter Securities Limited
Analyst: Tanushree Jain (tnjain@bellpotter.com.au)
Bell Potter initiated coverage on 8 December 2017.
For copies of current reports contact Bell Potter.
| 15 February 2019 | |
| 30 April 2018 |
Interim data from Phase 1 LOXL-2 program strengthen partnering prospects |
| 16 February 2018 | 1H18 Results - no material change from unaudited results released earlier |
| 1 February 2018 | |
| 11 January 2018 |
BI milestone strengthens balance sheet, LOXL-2 moves into the clinic |
| 8 December 2017 |
Emerging as a key player in multi-billion dollar NASH market |
Bioshares
Editors: David Blake and Mark Pachacz (info@bioshares.com.au)
Read Bioshares most recent reports:
| 25 February 2019 |
Pharmaxis Tackles the Intractable |
| 25 January 2019 |
Pharmaxis' LOXL2 Program Ready for a Deal |
| 10 December 2018 |
Pharmaxis Investor Briefing Summary |
| 12 October 2018 |
More Positive Phase I Data from LOXL2 Program |
| 13 August 2018 | Pharmaxis strengthens balance sheet ahead of LOXL2 licensing deal |
| 20 July 2018 | Interview with Dr Kathleen Metters |
| 8 May 2018 |
Pharmaxis – a drug developer with a deal making record |
| 5 February 2018 | A busy year for Pharmaxis – multiple trial readouts ahead |
| 8 September 2017 |
Pharmaxis – Boehringer selects diabetic retinopathy as second indication |
| 4 September 2017 |
Pharmaxis' partner starts phase II NASH trial |
| 24 March 2017 |
Three share price drivers for Pharmaxis |
| 28 October 2016 | Pharmaxis. All attention on NASH for Pharmaxis |